EzySpot

Similar stories

RAD140 Inhibitor 7 years 1 week ago

Product NameRAD140
Catalog Number1182367-47-0

RAD140 is a potent, orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM).IC50 value: 7 nM (Ki, fot androgen receptor).Target: androgen receptor
Molecular Weight393.83
Molecular FormulaC20H16ClN5O2
QuantityGrams-Kilos

Vorinostat Inhibitor 6 years 22 weeks ago

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM.
Reference Reading
1. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor
Marian Iwamoto • Evan J. Friedman •Punam Sandhu • Nancy G. B. Agrawal. Cancer Chemother Pharmacol (2013) 72:493–508
Vorinostat is an HDAC inhibitor currently marketed in the United States and other countries for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) who have progressive disease, persistent, or recurrent disease following two systemic therapies. Vorinostat inhibits the enzymatic activity of Class I (HDAC1, HDAC2, HDAC3) and Class II (HDAC6) HDACs at nanomolar concentrations (IC50<86 nM). A clinical study of vorinostat in patients with stage Ib and higher CTCL, who had failed to two systemic therapies (one containing bexarotene), demonstrated a 30 % overall objective response. An additional study in refractory CTCL patients demonstrated a similar response rate of 31 %.

Alfuzosin HCl inhibitor 6 years 22 weeks ago

Alfuzosin HCl is an alpha1 receptor antagonist used to treat benign prostatic hyperplasia (BPH).
Molecular Weight 425.91
Molecular Formula C19H28ClN5O4
Adrenergic Receptor
The aim of the present work was to develop simple and sensitive kinetic spectrophotometric methods for the determination of alfuzosin HCl in bulk and in its pharmaceutical preparations using alkaline potassium permanganate as an oxidizing agent.

Cyt387 Inhibitor 6 years 49 weeks ago

Cyt387, also called Momelotinib, under the IUPAC name N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide, is an ATP competitive inhibitor of JAK1 (IC50 = 11 nM) and JAK2 (IC50 = 18 nM) with potential antineoplastic activity, which may result result in the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells.

GW3965 inhibitor 6 years 49 weeks ago

GW3965 is a potent, selective LXR agonist for hLXRα and hLXRβ. When screened against a panel of nuclear receptors, it cross-reacted with only the pregnane X receptor (PXR). In Vitro: Recruit the steroid receptor coactivator 1 to human LXRα with EC50 of 125 nM in a cell-free ligand-sensing assay

Quizartinib inhibitor 6 years 49 weeks ago

Quizartinib is an orally available small molecule with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis.

Mk-2206 inhibitor 6 years 45 weeks ago

MK2206 is a Akt inhibitor, is also an orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner